Online inquiry

IVTScrip™ mRNA-Anti-CD47, SRF-231(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ15043MR)

This product GTTS-WQ15043MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets CD47 gene. The antibody can be applied in Cancers, Multiple myeloma (MM) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_001777.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 961
UniProt ID Q08722
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD47, SRF-231(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ15043MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ9151MR IVTScrip™ mRNA-Anti-EGFR, IMGN-289(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA IMGN-289
GTTS-WQ7971MR IVTScrip™ mRNA-Anti-IL7R, GX-17(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA GX-17
GTTS-WQ1408MR IVTScrip™ mRNA-Anti-MUC16, ACA125(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ACA125
GTTS-WQ3641MR IVTScrip™ mRNA-Anti-FGFR2, BAY 1187982(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA BAY 1187982
GTTS-WQ6662MR IVTScrip™ mRNA-Anti-MUC16, DMUC5754A(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA DMUC5754A
GTTS-WQ6753MR IVTScrip™ mRNA-Anti-EGFR, DS 992(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA DS 992
GTTS-WQ15507MR IVTScrip™ mRNA-Anti-FCGRT, UCB-7665(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA UCB-7665
GTTS-WQ12275MR IVTScrip™ mRNA-Anti-CD274, MSB-0010718C(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA MSB-0010718C
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW